andrew seidman, md: efficacy data supporting the use of eribulin mesylate
Published 8 years ago • 96 plays • Length 0:49Download video MP4
Download video MP3
Similar videos
-
1:39
joyce o’shaughnessy, md: efficacy data supporting the use of eribulin mesylate
-
1:34
andrew seidman, md: main indications for dose reduction with eribulin
-
1:34
andrew seidman, md: different mechanisms of action in eribulin
-
0:58
andrew seidman, md: candidacy for eribulin therapy
-
1:10
dr. andrew d. seidman on targeted treatments in breast cancer
-
1:20
dr. andrew d. seidman on the lack of a biomarker in certain breast cancers
-
0:44
andrew seidman, md: third-line options to prolong life
-
0:48
andrew seidman, md: treatment goals for patients with tnbc
-
1:48
dr. andrew seidman discusses the management of patients with brain metastases
-
1:09
andrew seidman, md: principle third-line options for patients with metastatic tnbc
-
6:51
treatment with eribulin mesylate in metastatic breast cancer
-
0:54
dr. seidman on ixabepilone in patients with aggressive breast cancer
-
1:23
dr. kaufman discusses the use of eribulin in metastatic breast cancer
-
1:18
dr. christopher twelves on eribulin mesylate in combination therapies for breast cancer
-
1:58
dr. alvarez on updated findings with eribulin in patients with her2 breast cancer
-
1:58
dr. twelves on a pooled analysis of eribulin in breast cancer
-
11:28
recent data on eribulin in metastatic breast cancer patients from sabcs
-
1:11
joyce o’shaughnessy, md: candidacy for eribulin therapy
-
5:25
eribulin in metastatic breast cancer